Takeda's Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial - Argus Press

Takeda's Dengue Vaccine Candidate Meets Primary Endpoint in Pivotal Phase 3 Efficacy Trial  Argus Press

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Jan 29, 2019--Takeda Pharmaceutical Company Limited [ TSE:4502 / NYSE:TAK ] (“Takeda”) today ...



Comments

Popular posts from this blog

SARS-CoV-2 virus may be shed for much longer periods by some infected patients, study shows - News-Medical.Net

This Nurse Built a Clinic in the Sierra Leone Village Where She Grew Up. That’s Just the Beginning. - Direct Relief